LETTER

Corticosteroids in H1N1, non-viral, and COVID-19 ARDS



Kyoung-Eun Kwon¹, Sun-Young Jung^{1,2}, Moon Seong Baek³ and Won-Young Kim^{3,4*}

© 2022 Springer-Verlag GmbH Germany, part of Springer Nature

Dear Editor,

The impact of corticosteroids on the outcomes of acute respiratory distress syndrome (ARDS) is controversial. This study was performed as a large-scale analysis of Korean health insurance claims data to determine whether ARDS etiology, baseline characteristics, or dosage of, duration of treatment with, and type of steroids modified the association between corticosteroid use and mortality among patients with ARDS.

Adult (age \geq 18 years) patients with 2009 influenza A (H1N1) (May 2009-April 2010), non-viral (January 2015-April 2019), or coronavirus disease 2019 (COVID-19) ARDS (January-December 2020) who received mechanical ventilation were included. Corticosteroid use was defined as at least one dose for intravenous dexamethasone, hydrocortisone, or methylprednisolone during the hospitalization. Logistic regression analyses were performed for 30- and 180-day mortality with corticosteroid use as an independent variable and age, sex, Charlson Comorbidity Index (CCI), immunosuppression, hospital type, organ dysfunction, and extracorporeal membrane oxygenation as covariates. Separate analyses were performed to ascertain the associations of dosage of, duration of treatment with, and type of steroids. The associations between corticosteroid use and mortality were also assessed with stratification according to age,

³ Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Chung-Ang University Hospital, Chung-Ang University College of Medicine, 102 Heukseok-ro, Dongjak-gu, Seoul 06973. Korea

Full author information is available at the end of the article

Kyoung-Eun Kwon and Sun-Young Jung contributed equally to this work.



CCI, number of organ dysfunctions, and immunosuppression. All statistical analyses were performed using SAS software (version 9.4; SAS Institute, Cary, NC, USA).

Among 18,106 included patients (mean [standard deviation] age, 67.4 [14.7] years; men, 63%), 3461 (19%), 6862 (38%), and 7783 (43%) were diagnosed with H1N1, nonviral, and COVID-19 ARDS, respectively (eFig. 1). The baseline characteristics and clinical outcomes are shown in eTables 1 and 2. Corticosteroids were associated with decreased 30- and 180-day mortality in non-viral ARDS, but were not associated with decreased 180-day mortality in H1N1 or COVID-19 ARDS (Fig. 1). Furthermore, corticosteroids for > 3 days were associated with decreased 30- and 180-day mortality in non-viral ARDS. However, these findings were not observed for 180-day mortality in H1N1 ARDS, and an even higher risk of 180day mortality was observed in COVID-19 ARDS. Recent studies have shown that patients with COVID-19 ARDS who received long-term corticosteroids had higher rates of survival [1, 2]; however, none of them evaluated longterm mortality. As corticosteroids can delay viral clearance [3], it might be necessary to assess the outcomes after 28 days for viral ARDS.

Dexamethasone was associated with decreased 30- and 180-day mortality among all patients with ARDS, while methylprednisolone was associated with increased 180-day mortality in H1N1 or COVID-19 ARDS (Fig. 1). Previous meta-analyses among patients with ARDS revealed no differences in survival benefit between steroid types [1, 4]; however, long-term mortality was not assessed. There may be a strong association between methylprednisolone and muscle weakness in patients receiving mechanical ventilation [5]. In H1N1 ARDS, corticosteroids were associated with decreased 30-day mortality in older patients (≥ 65 years) (eFig. 4). In COVID-19 ARDS, corticosteroids were associated with increased 180-day

^{*}Correspondence: wykim81@cau.ac.kr

| | No. of deaths/patients (%) | | adjusted OR (95% CI) | No. of deaths/patients (%) | | adjusted OR (95% CI) |
|------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|------------------|----------------------------------------------------------|--------------------------------------------------------|----------------------|----------------------------------------------------------|
| a H1N1 ARDS (n=3461) | | | | | | |
| No use | 455/1492 (30.5) | | ref | 764/1492 (51.2) | | ref |
| Steroid use | 564/1969 (28.6) | ⊢ ∎- | 0.86 (0.74-1.01) | 1057/1969 (53.7) | ⊦⊨⊸ | 1.10 (0.95-1.28) |
| Cumulative dose of steroid <250 mg ≥250 mg | 381/1252 (30.4) 183/717 (25.5) | | 0.93 (0.79-1.11) 0.74 (0.60-0.92) | 678/1252 (54.2) 379/717 (52.9) | +∎-i ++∎-i | 1.10 (0.93-1.30) 1.11 (0.91-1.35) |
| Total days of steroid use <3 days ≥3 days | 397/1266 (31.4) 167/703 (23.8) | | 1.01 (0.85-1.20) 0.63 (0.51-0.78) | 663/1266 (52.4) 394/703 (56.1) | | 1.07 (0.90-1.26) 1.17 (0.95-1.43) |
| Type of steroid Hydrocortisone Methylprednisolone Dexamethasone | 171/445 (38.4) 269/901 (29.9) 124/623 (19.9) | | 1.24 (0.98-1.56) 0.92 (0.76-1.12) 0.56 (0.44-0.71) | 265/445 (59.6) 502/901 (55.7) 290/623 (46.6) | | 1.17 (0.92-1.48) 1.23 (1.02-1.48) 0.91 (0.74-1.12) |
| b non-viral ARDS (n=6862) | | | | | | |
| No use | 955/1691 (56.5) | | ref | 1308/1691 (77.4) | | ref |
| Steroid use | 2080/5171 (40.2) | ⊢∎⊣ | 0.53 (0.47-0.60) | 3306/5171 (63.9) | HEH | 0.54 (0.47-0.61) |
| Cumulative dose of steroid <250 mg ≥250 mg | 1278/2849 (44.9) 802/2322 (34.5) | ⊢∎⊣ ⊢∎⊣ | 0.64 (0.56-0.73) 0.41 (0.36-0.47) | 1870/2849 (65.6) 1436/2322 (61.8) | ⊢∎⊣ ⊢∎⊣ | 0.58 (0.50-0.67) 0.48 (0.41-0.56) |
| Total days of steroid use <3 days ≥3 days | 1256/2381 (52.8) 824/2790 (29.5) | +∎- +∎-i | 0.88 (0.77-1.00) 0.31 (0.27-0.36) | 1728/2381 (72.6) 1578/2790 (56.6) | ⊢∎⊣ | 0.81 (0.70-0.95) 0.37 (0.32-0.43) |
| Type of steroid Hydrocortisone Methylprednisolone Dexamethasone | 532/906 (58.7) 1248/2382 (52.4) 300/1883 (15.9) | ⊦∎⊣ ⊧∎⊣ ■⊣ | 1.11 (0.94-1.31) 0.86 (0.75-0.98) 0.15 (0.13-0.18) | 733/906 (80.9) 1881/2382 (79.0) 692/1883 (36.8) | ┝╼┤ | 1.26 (1.02-1.55) 1.13 (0.96-1.33) 0.18 (0.15-0.21) |
| c COVID-19 ARDS (n=7783) | | | | | | |
| No use | 885/2917 (30.3) | | ref | 1333/2917 (45.7) | | ref |
| Steroid use | 1296/4866 (26.6) | H | 0.73 (0.66-0.82) | 2495/4866 (51.3) | | 1.12 (1.01-1.24) |
| Cumulative dose of steroid <250 mg ≥250 mg | 878/3134 (28.0) 418/1732 (24.1) | ⊢∎⊣ ⊨∎⊣ | 0.77 (0.68-0.87) 0.66 (0.57-0.76) | 1584/3134 (50.5) 911/1732 (52.6) | ;∎⊣ ⊢∎⊣ | 1.06 (0.95-1.18) 1.24 (1.09-1.41) |
| Total days of steroid use <3 days ≥3 days | 819/2860 (28.6) 477/2006 (23.8) | ⊦∎⊣ ⊢∎⊣ | 0.82 (0.73-0.93) 0.61 (0.53-0.70) | 1381/2860 (48.3) 1114/2006 (55.5) | ;=; ;=; | 1.00 (0.89-1.12) 1.32 (1.17-1.50) |
| Type of steroid Hydrocortisone Methylprednisolone Dexamethasone | 470/1153 (40.8) 555/1896 (29.3) 271/1817 (14.9) | +=- +=- | 1.23 (1.06-1.43) 0.86 (0.75-0.98) 0.38 (0.32-0.45) | 716/1153 (62.1) 1024/1896 (54.0) 755/1817 (41.6) | ⊢∎⊣ -∎- -∎- | 1.46 (1.26-1.70) 1.25 (1.10-1.42) 0.85 (0.74-0.96) |
| 0.1 1 1.8 0.1 1 1.8 Odds ratio (95% CI) Odds ratio (95% CI) 0dds ratio (95% CI) 30-day mortality 180-day mortality | | | | | | |

Fig. 1 Associations between corticosteroid use or dosage of, duration of treatment with, and type of steroids and 30- and 180-day mortality in **a** H1N1, **b** non-viral, or **c** COVID-19 ARDS. The numbers and percentages of patients who died according to each risk factor and the resulting odds ratios. For steroid use, the odds ratios were adjusted for age, sex, Charlson Comorbidity Index, immunosuppression, hospital type, organ dysfunction, steroid use, neuromuscular blocking agent use, and extracorporeal membrane oxygenation. For cumulative dose of steroid, total days of steroid use, and type of steroids, the odds ratios were adjusted for age, sex, Charlson Comorbidity Index, immunosuppression, hospital type, organ dysfunction, neuromuscular blocking agent use, and extracorporeal membrane oxygenation. *ARDS* acute respiratory distress syndrome; *COVID-19* coronavirus disease 2019; *H1N1* 2009 influenza A

mortality in patients with less organ dysfunction (<3) (eFig. 6).

Corticosteroid use was disproportionately associated with long-term mortality in viral and non-viral ARDS. Additional studies evaluating its use other than dexamethasone for long-term mortality in COVID-19 ARDS are warranted.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1007/s00134-022-06891-y.

Author details

¹ College of Pharmacy, Chung-Ang University, 84 Heukseok-ro, Dongjak-gu, Seoul 06974, Korea. ² Department of Global Innovative Drugs, Chung-Ang University, 84 Heukseok-ro, Dongjak-gu, Seoul 06974, Korea. ³ Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Chung-Ang University Hospital, Chung-Ang University College of Medicine, 102 Heukseok-ro, Dongjak-gu, Seoul 06973, Korea. ⁴ Biomedical Research Institute, Chung-Ang University Hospital, 102 Heukseok-ro, Dongjak-gu, Seoul 06973, Korea.

Author contributions

K-EK participated in the data acquisition, data analysis, and draft of the manuscript. S-YJ participated in the data acquisition, data analysis and interpretation, and helped to revise the manuscript for important intellectual content. MSB participated in the data interpretation and helped to revise the

manuscript for important intellectual content. W-YK participated in the conception and design of study, data interpretation, and draft of the manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by the research grant from Biomedical Research Institute, Chung-Ang University Hospital (2020) and the National Research Foundation of Korea grant funded by the Korea government (Ministry of Science, ICT & Future Planning) (2022R1F1A1067609). The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.

Declarations

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

The study protocol for analysis of de-identified patient data was exempted from review by the Institutional Review Board of Chung-Ang University (1041078–202007-HR-180–01).

Consent to participate

Not applicable.

Consent for publication Not applicable.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 17 August 2022 Accepted: 8 September 2022 Published: 29 September 2022

References

- 1. Chaudhuri D, Sasaki K, Karkar A et al (2021) Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and meta-analysis. Intensive Care Med 47:521–537
- 2. Torres A, Motos A, Cillóniz C et al (2022) Major candidate variables to guide personalised treatment with steroids in critically ill patients with COVID-19: CIBERESUCICOVID study. Intensive Care Med 48:850–864
- Giannella M, Alonso M, Garcia de Viedma D et al (2011) Prolonged viral shedding in pandemic influenza A(H1N1): clinical significance and viral load analysis in hospitalized patients. Clin Microbiol Infect 17:1160–1165
- 4. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne JAC, Murthy S et al (2020) Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA 324:1330–1341
- Herridge MS, Cheung AM, Tansey CM et al (2003) One-year outcomes in survivors of the acute respiratory distress syndrome. N Engl J Med 348:683–693